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Abstract
Metastasis, drug resistance and recurrence in cancer are regulated by the tumor microenvironment. 
This review describes recent advances in understanding how cancer cells respond to extracellular 
environmental cues via integrins, how to build engineered microenvironments to study these 
interactions in vitro and how nanomaterials can be used to detect and target tumor 
microenvironments.
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Introduction
Cells are responsive to the biochemical and biomechanical features of the extracellular 
matrix (ECM). These responses (e.g., proliferation, apoptosis, migration and differentiation) 
are crucial for health at all levels. Cancer cells share many of the responsive properties of 
healthy cells. However, they differ from normal cells because their responses to ECM are 
often dysregulated and they exhibit drug resistance and the ability to form recurrent tumors. 
Understanding how cancer cells respond to ECM cues provides access to new avenues for 
treatment complementary to our current arsenal of cancer therapies.
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In this short review, we will discuss recent advances in understanding how cancer cells 
respond to their environment via integrins with a particular focus on the mechanobiological 
properties of the ECM (Figure 1). We will also present recent findings on how the size-scale 
provided by nanomaterials can be used to change these environments for therapeutic 
purposes.
Integrins and cancer cells
Integrins are transmembrane glycoproteins that mediate interactions between cells and the 
ECM and link the ECM to the cytoskeleton [1]. Integrins sense the ECM and relay this 
information to downstream signaling pathways to control cell movement, growth and gene 
expression [1]. This function is of considerable importance in cancer because the ability of 
integrins to interact with the ECM in the tumor microenvironment and sense biochemical 
and biomechanical perturbations in this ECM is a key determinant of tumor growth and 
progression to metastatic disease [2]. Therefore the ECM is a key determinant of tumor 
growth and progression to metastatic disease [2]. Indeed, the literature is full of studies that 
describe the contribution of integrins to various aspects of cancer cell behavior. Some of the 
more interesting and provocative work in this area that has emerged recently relates to the 
importance of ECM–integrin interactions in the function of cancer stem cells (CSCs) and 
metastasis and the ability of integrins to transduce mechanical forces generated by the ECM 
(see below). Although these roles are not mutually exclusive, they will be discussed 
separately here.
CSCs
Most tumors harbor a population of cells with characteristics of stem cells including the 
ability to self-renew and populate new tumors [3,4]. This population, often referred to as 
CSCs or tumor-initiating cells, is resistant to most standard chemotherapies and thought to 
contribute to tumor dormancy and recurrence. CSCs differ from non-CSCs in their 
expression of specific integrins and these integrins are frequently used as cell surface 
markers to enrich for CSC populations [5]. Notable examples include the α6 integrins (α6β1 
and α6β4) and the αvβ3 integrin [2]. Moreover, it has become increasingly apparent that 
specific integrins contribute to sustaining stem cell properties by transducing cues from the 
ECM present in the CSC niche [6–8]. CSC niches are complex microenvironments primarily 
comprising CSCs, non-CSCs (cancer-associated fibroblasts, inflammatory cells) and ECM, 
as well as secreted factors (cytokines, growth factors) [8]. The CSC niche can be considered 
as a specialized form of the tumor microenvironment that functions to maintain stem cell 
properties, including self-renewal [8].
The biochemical and biomechanical properties of the ECM in the CSC niche exert profound 
effects on CSC function. Tenascins, periostin and laminins are among the ECM proteins that 
have been implicated in regulating CSC function [2,8]. The laminins are of particular 
interest in this regard because they exemplify the specificity of ECM cues in controlling 
CSCs. Among this large family of ECM proteins, one laminin (LM511) appears to be crucial 
for maintaining stemness. Breast CSCs, for example, deposit a LM511 matrix that sustains 
stem cell properties (self-renewal and tumor initiation; Figure 2) [7]. Surface-bound LM511 
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can be used as a marker to enrich for CSCs and, potentially, to detect CSCs in tumor 
sections [7]. Interestingly, LM511 is recognized by a specific, cytoplasmic domain splice 
variant of the α6β1 integrin (α6Bβ1) and this interaction activates a crucial signaling 
pathway involving the Hippo transducer TAZ which is necessary for the function of breast 
CSCs [7]. These findings reveal the exquisite specificity of ECM–integrin interactions in 
regulating stemness because only one of the two splice variants of the α6β1 integrin has the 
ability to recognize a specific laminin, which is crucial for stemness. This specificity 
provides opportunities for therapeutic targeting of CSCs, which has become the holy grail of 
cancer therapy. Future work should focus on understanding the unique biochemical and 
biomechanical properties of LM511 that confer stemness compared to other laminins and 
the recognition of this laminin by α6Bβ1.
The ability of integrins to promote stemness can occur independently of binding to ECM. 
This scenario is exemplified best by studies on the αvβ3 integrin, which contributes to the 
function of mammary and breast CSCs by enhancing the expression of Slug, a transcription 
factor that is a master regulator of stemness [9]. Antagonists that compete for αvβ3 ligand 
binding have no effect on mitigating stem cell properties [10]. The ability of αvβ3 to 
promote stemness in the absence of ECM engagement provides autonomy and self-
sufficiency to CSCs. Nevertheless, it is also evident that CSCs are dependent on cues from 
secreted factors, as well as other ECM–integrin interactions as described above. Clearly, a 
systems approach is needed to integrate the complex array of signals from the CSC niche 
and those intrinsic to CSCs that impact stemness.
Metastasis
The concept of the premetastatic niche provides an ideal example of the importance of 
external cues in cancer progression. This niche is a specialized microenvironment, 
comprising ECM (especially tenascin-C and periostin) and other molecules, which forms at 
potential metastatic sites in response to cues from the primary tumor [11,12]. Understanding 
how the primary tumor communicates the formation of the niche before the arrival of tumor 
cells is a fascinating problem. Recent studies implicate a key role for exosomes, which are 
small membrane vesicles that contain DNA, RNA, proteins and lipids [13]. Exosomes 
formed from primary tumor cells have the potential to home in distant organs and facilitate 
formation of the premetastatic niche [14].
An exciting advance in this field is the discovery that exosome integrins determine the organ 
specificity of the premetastatic niche and subsequent metastasis [15]. Exosomes destined for 
the lung, for example, express the α6β4 integrin, which is a laminin receptor [16], and are 
taken up by laminin-rich cells in the lung [14]. The fusion of these exosomes and their 
associated content with resident cells contributes to the formation of the premetastatic niche. 
These data substantiate previous work implicating the α6β4 integrin in metastasis and they 
strengthen its potential as a therapeutic target [17]. They also raise several provocative and 
timely questions. Given that laminin is present in all organs, what is distinct about the 
laminin in the lung (isoform specificity, location, mechanical properties) that enables it to 
function as a cue for α6β4-containing exosomes? Another intriguing consideration is how 
the formation of specific exosomes is regulated in the primary tumor. Given that exosomes 
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are formed by the fusion of multivesicular endosomes with the plasma membrane [7], what 
are the signals that trigger the formation of α6β4-containing exosomes for example? Is their 
formation linked to integrin endocytosis and recycling [18]? It is worth noting in this context 
that hypoxia selects for cells with metastatic potential [19], increases exosome formation 
and stimulates trafficking of the α6β4 integrin [20].
Mechanobiology and cancer
Studying the ability of a cell to sense and respond to mechanical cues has emerged as a field 
in itself over the past 20 years, and the importance of the mechanical environment on cell 
and/or tissue behavior is now appreciated by engineers and biologists alike. Growing 
evidence is proving that the ECM plays a crucial part in regulating tumor growth and 
metastasis [21], and stiffness is one of the ECM features responsible for tumor evolution. 
Tumor ECM is notoriously stiff (up to tens of kPa) relative to healthy tissue (hundreds of Pa) 
[22]; a difference that is associated with extensive changes in the metastatic potential of cells 
within the tumor [23]. The cellular response to mechanical influences from the ECM is 
mediated by integrins that not only provide tissue-specific cell attachment to ECM proteins 
but also activate biochemical signaling networks in response to static and dynamic 
mechanical forces [24]. A salient example of this phenomenon that relates to the previous 
discussion of integrins is that simply increasing ECM stiffness is sufficient to induce the 
malignant transformation of normal mammary epithelial cells, a process that is mediated by 
α6β4 integrin signaling [25,26].
Tumor stiffening is derived from an increase in fibrillar type 1 collagen, deposited by 
cancer-associated fibroblasts (CAFs) [27] and adipogenic stem cells (ASCs) [28]. During 
tumor growth, collagens become increasingly fibrillar and organize into tight bundles. Some 
propose that collagen reorganization [29] and tumor (and stroma) stiffness [30] could be 
used as a prognostic tool for metastatic risk or progression in patients via imaging or 
minimally invasive biopsy.
Metastasis
After cells have invaded the primary tumor stroma and intravasated local vasculature, those 
few cells that are able to survive the journey will eventually encounter secondary tissues that 
are biochemically and mechanically diverse. The mechanosensing of cells and these 
destination tissues is a newer, but active, area of research. Researchers are using a variety of 
techniques to quantify the rigidity of these tissue sites. Examples include brain tissue (1–2 
kPa in Young’s modulus) [31], lung (2–8 kPa) [32], trabecular and cortical bone being (~10 
GPa) and bone marrow (0.3–24.7 kPa) [33]. Engineers are using these analyses as 
inspiration to create in vitro model systems that capture the mechanical features of these 
diverse tissues [34], with the goal of elucidating the mechanisms of this mechanosensing, 
and eventually developing drugs to abrogate it.
Preliminary evidence points to tissue mechanics, alongside ECM binding [35], as one aspect 
that controls tissue-specific metastatic spread. Kostic et al. showed that cells that typically 
spread to certain tissues (e.g., brain, bone) also migrated faster and grew faster on substrates 
that were mechanically close to those destination tissues [36]. In a comparative study, 
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McGrail et al. demonstrated that ovarian cancer cell lines proliferated more and migrated 
faster on softer gels compared with breast cancer cells [37]. The authors suggest that this 
difference in migration rates mirrors the observation that ovarian cancer generally 
metastasizes to softer tissues than breast cancer. More-complex systems have emerged with 
the ability to combine mechanical cues with other facets of the tumor microenvironment, 
including vascularization [38], or tissue-specific features, typically from decellularized 
tissue sources [39]. What is needed to catapult these phenomenological studies into 
therapeutic targets is to identify the signaling networks downstream of integrin binding 
responsible for translating the mechanical signaling to metastasis. One recent example is the 
Rho/ROCK pathway – implicated in stiffness-mediated metastasis [27]. Another is the 
emerging role of YAP/TAZ as mechanotransducting nodes in the Hippo pathway [40]. 
Coupling these in vitro systems with phosphoproteomic and genomic sequencing could 
eventually connect the important studies in carefully controlled microenvironments to 
interrogation of integrin-mediated signaling for in vivo and clinical utility to stop metastasis 
from stiff tumors, or halt their ability to reach secondary sites with a certain mechanical 
profile.
Drug resistance
Drug resistance in cells and patients is a well known problem in cancer. During drug 
development, potential drug resistance can be missed, because chemotherapeutics and small 
molecule drugs are screened in ‘plastic’ microenvironments before preclinical and clinical 
trials, and these plastic environments do not resemble the natural environment of a cell or 
tumor. There is currently emphasis on the intracellular and genetic mechanisms of drug 
resistance. However, to make a paradigm shift in this field, many are now beginning to 
account for the mechanical environment of the cell as it responds to drugs. Given that 
mechanics regulate metastasis and tumor growth, similar intracellular proteomic networks 
could be rewired during tumor stiffening that hinder the efficacy of cancer drugs.
The ideal in vitro drug-testing platform to parse the role of mechanics in drug response 
would present matrix cues (such as stiffness and cell-binding peptides) relevant to what 
cancer cells experience in vivo in a 3D, high-throughput manner. A recent example is a 4D 
lung model, in which circulating tumor cells were equally resistant to cisplatin in the model 
system as they were in vivo, results that were not captured on 2D surfaces [41]. Similarly, 
combining ovarian cancer cells with fibroblasts in a representative ECM system 
recapitulated in vivo drug response better than monoculture models [42]. These types of 
organotypic representations of tissue for drug screening are likely to become increasingly 
popular with the advent of patient-derived cultures [43]. These patient-derived systems are 
relatively low-throughput, and a high-throughput aspect is crucial to making it accessible to 
pharmaceutical companies. Synthetic hydrogels have been adapted into multi-well plates to 
overcome this throughput issue, the first of which uses polyacrylamide (PAA) gels to show 
that stiffness regulated cancer cell growth in the presence of a few candidate drugs [44]. 
Other 2D systems have more recently emerged, including other mechanisms to prepare PAA 
gels [45], and those based on polyethylene glycol (PEG) [46]. These examples include not 
only response to common chemotherapeutics (e.g., paclitaxel) [45] but also how signaling 
networks perturbed during ECM stiffening provide resistance to receptor tyrosine kinase 
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inhibitors (e.g., sorafenib, lapatinib) [46,47]. Ideally, future work will translate these initial 
results into better-informed drug treatment and monitoring, with delivery systems 
incorporating tissue-specific targeting facilitated by nanomaterials.
Nanomaterials for regulating cancer cell behaviors
Nanomaterials are materials with sizes between 1 and 100 nm, corresponding to a size-scale 
ranging from that of small proteins to large cellular organelles. They can be engineered in a 
particular way to represent some of the key features of ECM, such as hydrophobicity, charge 
and topology, providing unique tools for fundamental studies of cell–environment 
interactions and therapeutic applications [48].
Chemical environment and cell behavior
We have discussed above how the specific chemical signals provided by integrins and the 
mechanical environment of the ECM regulate cancer cell behavior. The physicochemical 
environment of the ECM likewise plays a significant part, as demonstrated by the role of cell 
glycosylation in cancer progression. This interplay has been studied using chemically 
modified surfaces of substrates, however control of chemical functionality and topology 
remain a challenge. Nanomaterials provide a tool for controlling both aspects by ‘painting’ 
on pre-functionalized nanomaterials. As an example, Cui et al. have recently used polymer-
functionalized nanoparticles to demonstrate that hydrophobic nanomaterials inhibit HeLa 
cell proliferation [49]. This study presented one axis of the physicochemical environment; 
however the ECM presents a range of stimuli including charge and topology as well as 
hydrophobicity. Tang et al. have used small (2 nm core) gold nanoparticles functionalized 
with a wide range of surface ligands to probe cell proliferation with four different cancer cell 
lines (Figure 3) [50]. These studies showed that cationic functionality enhanced cell 
proliferation. More interesting, however, was the fact that specific chemical moieties (e.g., 
aromatic groups) had differential responses between the cell lines studied. This outcome 
suggests that modulation of the local chemical environment of cells provides a potential 
strategy for selectively regulating cancer cell behavior, as discussed below.
The above studies used 2D cell culture techniques, which are clearly an abstraction of the 
3D nature of tumors. Grzincic and Murphy studied the effects of gold nanorods in 3D 
collagen matrices, discovering that these nanomaterials accelerated cell migration of breast 
tumor cells, enabling a rounded ‘amoeboid-like’ phenotype [51] not normally observed in 
2D systems.
Nanomaterials as environmental therapeutics
The broadest application of nanomaterials in medicine has been as delivery vehicles for 
therapeutic small molecules and biomacromolecules [52]. They have also been used as 
intracellular self-therapeutics for regulating cellular processes. Nanomaterials have recently 
emerged that mimic and/or alter the cellular environment, providing new strategies for 
nanotherapeutics. One particularly interesting application was the use of nanoparticles 
coated with ECM from tumor-associated fibroblasts to capture cancer cells, thereby 
preventing peritoneal metastasis [53]. Another example of a nanotherapeutic approach lies in 
Yoshii et al. Page 6













altering stemness of CSCs. The ability of CSCs to self-renew and differentiate into multi-
lineage provides a challenging yet potentially high-payoff target for therapeutic strategies. 
Just as environmental effects can be used to regulate normal stem cell differentiation, CSCs 
can be induced to differentiate through environmental cues. For instance, gadolinium 
fullerene Gd@C82(OH)22 was reported to block epithelial-to-mesenchymal transition of 
triple-negative breast cancer cells [54], without any toxicity to normal mammary epithelial 
cells. Gd@C82(OH)22 successfully suppressed breast tumor growth in vivo. Hydrophobicity 
appears to be an important consideration in CSC interactions, because graphene-oxide (GO) 
was also reported to work as a therapeutic strategy against CSCs via de-stemming, as 
demonstrated through a lack of spheroid formation [55].
Concluding remarks
The biochemical and biomechanical microenvironment of tumors is a key factor in 
metastasis and drug resistance. Understanding the part these factors play in cancer 
progression provides new strategies for therapeutics. We present here how biomolecules 
(e.g., integrins) and nanomaterials alter cancer cell behavior through chemical means, and 
how mechanobiology is a key factor in understanding and treating cancer progression. Taken 
together, this work shows that targeted presentation of external cues has the potential to 
complement current intracellular cancer therapy strategies.
Supplementary Material
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• Biomolecules including integrins are key factors in cancer progression
• Nanomaterials provide tools for regulating the chemical environment of 
cells
• Mechanobiology is an emerging determinant in designing cancer 
therapies
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Representative examples of how external cues dictate cell behavior.
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Surface-bound LM511 identifies breast cancer cells with stem cell properties. (a) Sections of 
human breast tumors were stained with an antibody that recognizes the a5 subunit of LM511 
using either immunohistochemistry (top) or immunofluorescence (bottom). Note the small 
number of cells with intense LMa5 staining on their surfaces (arrows). (b) Three primary 
human breast tumors (T1, T2 and T3) were dissociated and sorted by FACS using a LMa5 
Ab. Cells with low surface-bound LMa5 (P1, P3 and P4) were compared with cells with 
high surface-bound LMa5 (P2, P4 and P6) for their ability to form mammospheres. (c) Note 
that cells with high surface-bound LMa5 had the ability to form mammospheres. Adapted, 
with permission, from [7].
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Relationship between cell viabilities of four different cancer cells and different AuNP 
coatings for 2 nm core AuNPs immobilized on polystyrene surfaces. (a) A heat map of cell 
viability on different AuNP coatings. (b) Structures of ligands on the AuNPs. Adapted, with 
permission, from [50].
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